Going viral with cancer immunotherapy

Abstract

Oncolytic viruses were originally designed as tumour-lysing therapeutics. However, they also initiate systemic antitumour immune responses. Can these viruses be exploited to enhance antitumour immune responses, and how might they be combined with other cancer immunotherapies?

Authors

Lichty BD; Breitbach CJ; Stojdl DF; Bell JC

Journal

Nature Reviews Cancer, Vol. 14, No. 8, pp. 559–567

Publisher

Springer Nature

Publication Date

January 1, 2014

DOI

10.1038/nrc3770

ISSN

1474-175X

Associated Experts

Brian Lichty

Associate Professor, FHSMED

Visit profile

Labels